Assenagon Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Assenagon Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-590,153	Closed	-$40.2M	–	1511
2022 Q3	$40.2M	Buy	590,153 +421,383	+250%	+$23.2M	0.15%	131
2022 Q2	$5.39M	Buy	+168,770	New	+$4.94M	0.02%	519
2020 Q1	–	Sell	-29,571	Closed	-$2.35M	–	1048
2019 Q4	$2.35M	Buy	+29,571	New	+$1.75M	0.01%	399

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Assenagon Asset Management's GBT Position: Q4 2022 in Review

Assenagon Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 590,153 shares — an estimated $40.2M sold.

Assenagon Asset Management first reported a position in GBT in Q4 2019 and held it in 3 quarters. The position peaked at $40.2M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Assenagon Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Assenagon Asset Management sold 590,153 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $40.2M.
Assenagon Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 3 quarters.
Assenagon Asset Management's Global Blood Therapeutics, Inc. position peaked at $40.2M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Assenagon Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.